Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$78.61 USD

78.61
3,921,116

-0.63 (-0.80%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $78.62 +0.01 (0.01%) 7:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?

by Zacks Equity Research

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Zacks Equity Research

ITGR vs. EW: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Zacks Equity Research

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook

by Zacks Equity Research

Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.

Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Edwards Lifesciences (EW) Up 6.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.

Zacks Equity Research

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook

by Zacks Equity Research

DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Zacks Equity Research

Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip

by Zacks Equity Research

Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.

Zacks Equity Research

CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View

by Zacks Equity Research

CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.

Zacks Equity Research

West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales

by Zacks Equity Research

West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.

Sanghamitra Saha headshot

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include PepsiCo (PEP), The J.M. Smucker Co (SJM), AMC Entertainment (AMC), Edwards Lifesciences (EW) and Versus Systems (VS).

Zacks Equity Research

Edwards Lifesciences (EW) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Edwards Lifesciences (EW) Q3 Earnings Match Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 0.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More

by Urmimala Biswas

Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.

Nalak Das headshot

5 Large-Cap Stocks to Buy Ahead of Q3 Earnings This Week

by Nalak Das

We have narrowed our search to five large-cap stocks that are set to declare third-quarter earnings results this week. These are: EW, VICI, VMC, GLPI, MBLY.

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research

Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.

Zacks Equity Research

What's in Store for Option Care Health (OPCH) in Q3 Earnings?

by Zacks Equity Research

Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.

Zacks Equity Research

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.